| Ytd | 201.06% | |
| 1y | 246.49% |
| Open | 23.52 | Prev Close | 23.73 | Low | 22.59 | High | 24.35 | Mkt Cap | 742.00M |
| Vol | 192.57K | Avg Vol | 324.40K | EPS | -1.32 | P/E | N/A | Forward P/E | -4.77 |
| Beta | 0.40 | Short Ratio | 5.30 | Inst. Own | 6.95% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-03 | 50-d Avg | 20.63 | 200-d Avg | 11.56 | 1yr Est | 22.00 |
NVCT News
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analys
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analys
Wall Street analysts upgraded DTM, SEDG. Check out analyst ratings and price targets on Benzinga.
Top names on Wall Street have had their outlook changed by analysts, including downgrades and price
Top Wall Street analysts changed outlook on top names. See analyst ratings page for all changes. Con
Top Wall Street analysts changed outlook on top names. See analyst ratings for VTEX, FIS, and more.
Top analysts upgraded Fluence Energy, Dynatrace, and Advanced Micro Devices, Check out their ratings
Analysts change outlook on top names. See all rating changes, including upgrades/downgrades/initiati
Top Wall Street analysts changed their outlook on top names. See analyst ratings page for full list.
Analysts changed outlook on top names like BRCB, CMG and more. See ratings page for full list. CMG s
Top Wall Street analysts change outlook on top names. For full ratings, including upgrades and downg
Cantor Fitzgerald analyst Pete Stavropoulos initiates coverage on Nuvectis Pharma (NASDAQ:NVCT) w
NVCT's 97% three-month gain reflects optimism around its expanding pipeline, with NXP100 and NXP200
Nuvectis Pharma (NASDAQ:NVCT) reported quarterly losses of $(0.30) per share which missed the analys
FORT LEE, N.J., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" o
The mean of analysts' price targets for Nuvectis Pharma (NVCT) points to a 56.4% upside in the stock
First global approval of a once-daily, orally administered, Complement Factor B inhibitor Approval b
Nuvectis Pharma, Inc. (NASDAQ:NVCT) ("Nuvectis" or the "Company"), a clinical-stage
Fort Lee, NJ, July 23, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis” or
US stock futures higher with Nasdaq 100 up 150 points. Ryanair (RYAAY) shares fall after weak Q1 res
New report covers Nuvectis Pharma (NASDAQ: NVCT) as the company transitions from a single-drug oncol
The consensus price target hints at a 61.5% upside potential for Nuvectis Pharma (NVCT). While empir
Top Wall Street analysts changed their outlook on these top names. For a complete view of all rating
Roth Capital analyst Jonathan Aschoff maintains Nuvectis Pharma (NASDAQ:NVCT) with a Buy and rais
Does Nuvectis Pharma, Inc. (NVCT) have what it takes to be a top stock pick for momentum investors?
Gainers Creative Medical Tech (NASDAQ:CELZ) stock moved upwards by 242.5% to $2.77 during Tuesday&#
Gainers Abivax (NASDAQ:ABVX) shares increased by 36.0% to $130.74 during Tuesday's pre-market s
US stock futures up, Dow futures gain 100+ points. Concentrix Corp (CNXC) shares down 24% after weak
AeroVironment, Inc. (NASDAQ: AVAV) jumped 21.4% in pre-market trading after reporting strong financi
Nuvectis intends to use the net proceeds from the offering to continue to advance the development pr
FORT LEE, N.J., June 29, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (Nasdaq: NVCT), a clinical s
Gainers Gain Therapeutics (NASDAQ:GANX) stock rose 20.2% to $2.38 during Monday's after-market
Nuvectis Pharma, Inc. (NASDAQ:NVCT), a clinical stage biopharmaceutical company focused on the devel
FORT LEE, NJ, June 29, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (Nasdaq: NVCT), a clinical sta
Nuvectis Pharma (NVCT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about
Gainers Pulsenmore (NASDAQ:PLSM) shares moved upwards by 160.5% to $8.88 during Wednesday's reg
Nuvectis Pharma, Inc. (NVCT) Discusses Strategic In-Licensing Deal and Expansion Into Complement-Med
Nuvectis Pharma said on Monday it had licensed exclusive rights outside China to two experimental dr
Fort Lee, NJ, June 22, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) (“Nuvectis” or
The mean of analysts' price targets for Nuvectis Pharma (NVCT) points to a 57% upside in the stock.
Fort Lee, NJ, May 14, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or t
The average of price targets set by Wall Street analysts indicates a potential upside of 62.5% in Nu
FORT LEE, N.J., May 05, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or
Fort Lee, NJ, March 31, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or
FORT LEE, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" o